{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-035381","form_type":"8-K","ticker":null,"cik":"0001801777","company_name":"Applied Molecular Transport Inc.","filed_at":"2023-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.523495+00:00","generated_at":"2026-06-07T06:58:32.276440+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Applied Molecular Transport completes merger with Cyclo Therapeutics; AMTI becomes wholly owned subsidiary","bullets":["Each AMTI share converted into 0.1331 shares of Cyclo common stock at merger effective December 27, 2023.","AMTI requested Nasdaq to suspend trading and delist AMTI common stock; will file Form 15 to deregister.","All AMTI directors and officers ceased; former AMTI director Shawn Cross appointed to Cyclo board.","AMTI's charter and bylaws amended and restated per the Merger Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-035381","json":"https://secwatch.observer/filing/0001437749-23-035381.json","markdown":"https://secwatch.observer/filing/0001437749-23-035381.md","text":"https://secwatch.observer/filing/0001437749-23-035381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1801777/000143774923035381/0001437749-23-035381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1801777/000143774923035381/amti20231222_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:58:32.276440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dcbc6deae5","claim":"Shawn Cross was appointed as director at Applied Molecular Transport Inc..","evidence_excerpt":"Shawn Cross, a former director of AMTI, was appointed to the board of directors of Cyclo.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1801777/000143774923035381/0001437749-23-035381-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"4b4c0ad755573893cdb96db1204008771d5f1edd","claim":"Applied Molecular Transport Inc. underwent a change of control involving Cyclo Therapeutics, Inc. (closed 2023-12-27).","evidence_excerpt":"On December 27, 2023, Applied Molecular Transport Inc., a Delaware corporation (\"AMTI\"), completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023 (the \"Merger Agreement\"), by and among Cyclo Therapeutics, Inc., a Nevada corporation (\"Cyclo\"), Cameo Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Cyclo (\"Merger Sub\") and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the \"Merger\").","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1801777/000143774923035381/0001437749-23-035381-index.htm","confidence":0.99,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Cyclo Therapeutics, Inc."},{"label":"Closing","value":"2023-12-27"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}